The Maurice R. Greenberg CLCC provides coordinated and comprehensive care for adults and children with elevated levels of cholesterol including familial hypercholesterolemia. Our location within the Rogosin Institute’s Jack Dreyfus Clinic has fostered an additional focus on the prevention and treatment of atherosclerosis and heart disease in individuals with kidney disease. Our staff are integral members of the Program for Education of Patients with Advanced Kidney Disease (PEAK).
Rogosin’s work in lipid control began in the early 1980s when The Institute collaborated with The Rockefeller University to pioneer clinical research of LDL-apheresis, a procedure that lowers LDL cholesterol by more than 50%. Work done by Rogosin contributed to the 1996 FDA approval of the LDL-apheresis procedure developed by Kaneka America Corporation.
What does the CLCC do?
The CLCC at Rogosin was the first LDL-apheresis unit in the United States and it continues to treat children and adults with severe familial hypercholesterolemia. In addition to LDL-apheresis, the CLCC provides a full range of diagnostic and treatment services for adults and children. Individualized treatment at the CLCC may include diet and exercise modification, lipid lowering medication and when necessary, referral for other therapy.
Diet and exercise play an important role in the production and elimination of cholesterol. The nutritionists with the CLCC develop diet programs that are designed to improve each person’s lipid profile and overall health. They have decades of experience in teaching patients how to successfully improve their lipid profiles.
The CLCC is located within the Jack Dreyfus Rogosin Kidney Center outpatient facility at The Rogosin Institute, 505 East 70th street, second floor. For more information about the CLCC, call 212-746-1554.
The Pediatric CLCC (PCLCC) was established in 1989 to diagnose and treat children with inherited causes of extremely high cholesterol or triglyceride levels as early in life as possible. Early intervention can prevent conditions such as diabetes, kidney disease, heart disease, and obesity that are so difficult to treat in adulthood.
Lisa Hudgins, MD, director of the PCLCC, believes that children with risk factors for atherosclerosis need to be identified early and receive appropriate treatment.
Pediatric lipid disorder treatment options
Most children with lipid disorders can be treated with lifestyle counseling, such as diet and exercise. Medications are only used when diet and exercise are not effective. However, some with common genetic conditions may require medication by their teen years. One example is heterozygous familial hypercholesterolemia (FH), a condition that results when children inherit an abnormal gene from one parent or another. In FH, cholesterol levels are elevated from birth and are usually resistant to changes in diet.
Dr. Hudgins is recognized as one of the foremost authorities on treating children with homozygous FH. Untreated, these patients have LDL cholesterol levels above 500 mg/dL and can have heart attacks and die suddenly in adolescence or early childhood. These children are resistant to diet and exercise but newer cholesterol lowering medications maybe helpful. Some patients need LDL-apheresis to control their LDL cholesterol levels. For children who do not respond to LDL-apheresis, liver transplantation, performed in collaboration with the NewYork-Presbyterian/Columbia Center for Liver Disease and Transplantation, is an option.
For more information contact Lisa Hudgins, MD, at 212-746-6972.